全文获取类型
收费全文 | 1023篇 |
免费 | 39篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 14篇 |
妇产科学 | 7篇 |
基础医学 | 104篇 |
口腔科学 | 10篇 |
临床医学 | 95篇 |
内科学 | 298篇 |
皮肤病学 | 14篇 |
神经病学 | 60篇 |
特种医学 | 71篇 |
外科学 | 191篇 |
综合类 | 8篇 |
一般理论 | 1篇 |
预防医学 | 37篇 |
眼科学 | 26篇 |
药学 | 36篇 |
肿瘤学 | 87篇 |
出版年
2022年 | 8篇 |
2021年 | 16篇 |
2020年 | 13篇 |
2019年 | 12篇 |
2018年 | 14篇 |
2017年 | 12篇 |
2016年 | 26篇 |
2015年 | 26篇 |
2014年 | 40篇 |
2013年 | 32篇 |
2012年 | 86篇 |
2011年 | 92篇 |
2010年 | 64篇 |
2009年 | 46篇 |
2008年 | 81篇 |
2007年 | 76篇 |
2006年 | 59篇 |
2005年 | 72篇 |
2004年 | 55篇 |
2003年 | 54篇 |
2002年 | 44篇 |
2001年 | 5篇 |
2000年 | 6篇 |
1999年 | 8篇 |
1998年 | 11篇 |
1997年 | 8篇 |
1996年 | 4篇 |
1995年 | 2篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 4篇 |
1991年 | 2篇 |
1990年 | 5篇 |
1989年 | 4篇 |
1988年 | 6篇 |
1987年 | 5篇 |
1986年 | 5篇 |
1985年 | 7篇 |
1984年 | 7篇 |
1983年 | 2篇 |
1981年 | 4篇 |
1980年 | 4篇 |
1979年 | 3篇 |
1978年 | 8篇 |
1971年 | 1篇 |
1970年 | 2篇 |
1955年 | 1篇 |
1949年 | 7篇 |
1944年 | 1篇 |
1943年 | 1篇 |
排序方式: 共有1062条查询结果,搜索用时 31 毫秒
101.
Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men 总被引:3,自引:0,他引:3
Strasak A Ruttmann E Brant L Kelleher C Klenk J Concin H Diem G Pfeiffer K Ulmer H;VHM&PP Study Group 《Clinical chemistry》2008,54(2):273-284
BACKGROUND: The role of serum uric acid (SUA) as an independent risk factor for cardiovascular disease (CVD) remains controversial, and little is known about its prognostic importance for mortality from congestive heart failure (CHF) and stroke. Few large-scale epidemiologic studies with sufficient follow-up have addressed the association of SUA and CVD mortality in apparently healthy men across a wide age range. METHODS: A cohort of 83 683 Austrian men (mean age, 41.6 years) was prospectively followed for a median of 13.6 years. We used Cox proportional hazards models adjusted for established risk factors to evaluate SUA as an independent predictor for CVD mortality. RESULTS: The highest quintile of SUA concentration (>398.81 mumol/L) was significantly related to mortality from CHF (P = 0.03) and stroke (P <0.0001); adjusted hazard ratios (95% confidence interval) for the highest vs lowest quintiles of SUA were 1.51 (1.03-2.22) and 1.59 (1.23-2.04), respectively. SUA was not associated, however, with mortality from acute, subacute, or chronic forms of coronary heart disease (CHD) after adjustment for potential confounding factors (P = 0.12). Age was a significant effect modifier for the relation of SUA to fatal CHF (P = 0.05), with markedly stronger associations found in younger individuals. CONCLUSIONS: Our study demonstrates for the first time in a large prospective male cohort that SUA is independently related to mortality from CHF and stroke. Although increased SUA is not necessarily a causal risk factor, our results suggest the clinical importance of monitoring and intervention based on the presence of an increased SUA concentration, especially because SUA is routinely measured. 相似文献
102.
103.
104.
Yamasaki Y Narain S Yoshida H Hernandez L Barker T Hahn PC Sobel ES Segal MS Richards HB Chan EK Reeves WH Satoh M 《Arthritis and rheumatism》2007,56(2):596-604
OBJECTIVE: To investigate the clinical and immunologic significance of autoantibodies to RNA helicase A (RHA) in patients with systemic rheumatic diseases. METHODS: The study group comprised 1,119 individuals enrolled in the University of Florida Center for Autoimmune Diseases registry from 2000 to 2005. Diagnoses were based on standard criteria. Autoantibodies were analyzed by immunoprecipitation and Western blot assays. RESULTS: Anti-RHA was observed in 17 (6.2%) of 276 patients with systemic lupus erythematosus (SLE), 2 patients with antiphospholipid antibodies, and 3 other patients, but anti-RHA was not observed in any patient with polymyositis/dermatomyositis, systemic sclerosis, rheumatoid arthritis, or Sj?gren's syndrome. Anti-RHA was present in only 2.9% of African American patients, compared with 6.0% of white patients and 12-25% of patients of other races; this was in striking contrast to the frequency of anti-Sm in African American patients (27.2%). Among patients with SLE, anti-RHA was common in young patients (26% of those whose initial visit was at an age younger than 20 years versus 3-4% of those who were initially seen at ages 20-49 years) and at an early stage of disease (23% of those whose first clinic visit was within 1 year of disease onset versus 2-8% of those whose first visit was at least 1 year after disease onset). In 9 of 11 patients, levels of anti-RHA decreased to <10% of the initial value within 9-37 months, while levels of coexisting anti-Ro or anti-Su remained the same. New specificities developed in 2 patients (anti-nuclear RNP and anti-Sm, and anti-ribosomal P, respectively). These data suggest that the level of anti-RHA diminishes over time, and that anti-RHA is regulated via a mechanism different from that for other lupus-related autoantibodies. CONCLUSION: Anti-RHA is a new serologic marker for SLE. It is produced mainly in young non-African Americans at an early stage of their disease. Anti-RHA has a unique tendency to diminish over time. The production of anti-RHA may depend on a process restricted to early SLE, or it may be highly sensitive to treatment. 相似文献
105.
Characterization of a novel SCN5A mutation associated with Brugada syndrome reveals involvement of DIIIS4-S5 linker in slow inactivation 总被引:1,自引:0,他引:1
Casini S Tan HL Bhuiyan ZA Bezzina CR Barnett P Cerbai E Mugelli A Wilde AA Veldkamp MW 《Cardiovascular research》2007,76(3):418-429
OBJECTIVE: Mutations in SCN5A, the gene encoding the alpha-subunit of the cardiac sodium channel (Na(v)1.5), have been associated with various inherited arrhythmia syndromes, including Brugada syndrome (BrS). Here, we report the functional consequences of a novel missense SCN5A mutation, G1319V, identified in a BrS patient. The G1319V mutation is located in the loop connecting transmembrane segments 4 and 5 in domain III (DIIIS4-S5), a region so far considered to be exclusively involved in fast inactivation. METHODS: Whole-cell mutant (G1319V) and wild-type (WT) sodium currents (I(Na)) were studied in the Human Embryonic Kidney cell line (HEK-293) transfected with Na(v)1.5 alpha-subunit cDNA (WT or mutant) together with hbeta(1)-subunit cDNA, using the patch-clamp technique. RESULTS: Maximal peak I(Na) and persistent sodium current were similar in WT and channel G1319V channels. The G1319V mutation shifted the potential of half-maximal (V(1/2)) activation towards more positive potentials (+3.7 mV), thereby increasing the degree of depolarization required for activation. The V(1/2) of inactivation of G1319V channels was shifted by -6.0 mV compared to WT, resulting in a reduced channel availability. The change in the steady-state inactivation was completely due to a negative shift (-6.8 mV) of the voltage-dependence of slow inactivation, while the voltage-dependence of fast inactivation was unaffected. The fast component of recovery from inactivation of G1319V channels was slowed down. Finally, the G1319V mutation caused a two-fold increase in the propensity of the channels to enter the slow inactivated state. Reduction in I(Na) peak amplitude on repetitive depolarizations at short interpulse intervals (40 ms) was significantly more pronounced in G1319V compared to WT. Accordingly, carriers of the G1319V mutation showed marked QRS widening upon increases in heart rate during exercise testing, pointing to enhancement of slow inactivation. CONCLUSIONS: We identified the DIIIS4-S5 linker as a new region involved in slow inactivation of Na(v)1.5. The biophysical alterations of the G1319V mutation all contribute to a reduction in I(Na), in line with the proposed mechanism underlying BrS. 相似文献
106.
107.
Interest in the biology of the microtubule-associated protein tau, not only as a pathologic marker, but as a therapeutic target has surged considerably over the last few years. This is due, in part, to the discovery of mutations in tau causing a group of aggressively degenerative neurologic disorders characterized by abnormalities of tau very similar to what is seen in Alzheimer's disease where mutations in tau are absent. As these same mutations also precipitate authentic forms of neurofibrillary degeneration in tau transgenic mice, the gateways to testing therapeutic ideas preclinically have opened. Other Alzheimer's disease animal models have been notoriously bare of this feature, limiting their predictive power for clinical success. In this review, the authors discuss some of the main therapeutic ideas presently advanced in the field and their molecular rationales. 相似文献
108.
Autologous myoblasts and fibroblasts for female stress incontinence: a 1-year follow-up in 123 patients 总被引:1,自引:0,他引:1
Mitterberger M Marksteiner R Margreiter E Pinggera GM Colleselli D Frauscher F Ulmer H Fussenegger M Bartsch G Strasser H 《BJU international》2007,100(5):1081-1085
OBJECTIVE: To assess the efficacy and safety of the application of autologous myoblasts and fibroblasts for treating female stress urinary incontinence (SUI) after a follow-up of >/=1 year. PATIENTS AND METHODS: In all, 123 women with SUI (aged 36-84 years) were treated with transurethral ultrasonography-guided injections with autologous myoblasts and fibroblasts obtained from skeletal muscle biopsies. The fibroblasts were suspended in a small amount of collagen as carrier material and injected into the urethral submucosa, while the myoblasts were implanted into the rhabdosphincter. All patients were evaluated before and 12 months after the injection using the Incontinence and Quality of Life Instrument (I-QOL) scores, urodynamic variables, and morphology and function of the urethra and rhabdosphincter. RESULTS: At 1 year after implanting the cells, 94 of the 119 women (79%) were completely continent, 16 (13%) had a substantial improvement and nine (8%) a slight improvement. Four patients were lost to follow-up.The incontinence and I-QOL scores, and the thickness, contractility and electromyographic activity of the rhabdosphincter were significantly improved after treatment. CONCLUSIONS: These results show the efficacy and safety of transferring autologous myoblasts and fibroblasts in the treatment of female SUI, after a follow-up of 1 year. 相似文献
109.
Pharmacologic erection with intracavernosal injection for men with sexual dysfunction following irradiation: a preliminary report 总被引:1,自引:0,他引:1
L J Pierce R Whittington P M Hanno W English A J Wein R L Goodman 《International journal of radiation oncology, biology, physics》1991,21(5):1311-1314
Impotence is a possible consequence of treatment of pituitary adenomas and prostatic carcinomas. Following pituitary irradiation, the effect has been attributed to decreased gonadotrophins, while a variety of mechanisms, primarily vascular and neurogenic, have been proposed to explain the impotence following irradiation of prostatic carcinomas. Men with impotence of any etiology have been entered on a program to evaluate prospectively the efficacy of intracavernosal injection of vasoactive compounds in producing a satisfactory erection with pharmacologic means. Ten of these men had developed impotence following therapy for pituitary adenomas (2) or prostatic carcinomas (8). Test doses of 0.1 to 0.5 ml of a phentolamine (1 mg/ml) and papaverine (30 mg/ml) mixture were used; the dose was titrated to produce an erection deemed sufficient for vaginal penetration. All patients achieved a satisfactory response (i.e., tumescence and rigidity) lasting 10 minutes to 3 hours. Seven patients have continued in the pharmacologic erection program, with six patients functioning normally, and the remaining patient noting decreased tumescence after 18 months of treatment, but adequate erections are maintained with supplemental penile ring. Two patients have discontinued intracavernosal injections due to inconvenience, and one patient was lost to follow-up. Recent substitution of prostaglandin E1 (PGE1) has produced similar results and has replaced the phentolamine-papaverine combination. These preliminary results indicate that pharmacologic erection can be achieved in patients with impotence related to the treatment of pituitary and prostatic neoplasms and represents a reasonable alternative to implanted penile prostheses. 相似文献
110.
Gene therapy to create biological pacemakers 总被引:2,自引:0,他引:2
Boink GJ Seppen J de Bakker JM Tan HL 《Medical & biological engineering & computing》2007,45(2):167-176
Old age and a variety of cardiovascular disorders may disrupt normal sinus node function. Currently, this is successfully
treated with electronic pacemakers, which, however, leave room for improvement. During the past decade, different strategies
to initiate pacemaker function by gene therapy were developed. In the search for a biological pacemaker, various approaches
were explored, including β2-adrenergic receptor overexpression, down regulation of the inward rectifier current, and overexpression of the pacemaker
current. The most recent advances include overexpression of bioengineered ion channels and genetically modified stem cells.
This review considers the strengths and the weaknesses of the different approaches and discusses some of the different viral
vectors currently used. 相似文献